Selective caspase inhibitors and uses thereof
The present invention relates to compounds of Formula I, II, IVC, VIIIC, IXC, or XC and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, II, IVC, VIIIC, IXC, or XC are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases). Processes for synthesizing tripeptides are provided.
1. A compound according to Formula I:
wherein a is 0 or 1;
wherein b is 0 or 1 provided that when b is 0, a is 0;
wherein A is selected from the group consisting of H, C 1 -C 6 alkyl, aryl, heteroaryl, heterocyclyl, R 3 —OC(O)—, R 3 —CH 2 OC(O)—, and R 3 —S(O) 2 —;
wherein P2, P3, P4, and, when present, P5 and PX are each independently any (D) or (L) natural or non-natural amino acid residue;
wherein the line “-” when located between P2, P3, P4, P5, or PX represents a peptide bond or a peptidomimetic bond selected from the group consisting of CH 2 —NH, CO—CH 2 , azapeptide, and retro-inverso bonds;
wherein the wavy line represents either cis or trans orientation of R 1 and R 2 ;
wherein R 1 is selected from the group consisting of aryl, heteroaryl, heterocyclyl, C 2 -C 6 alkene-R 20 , SO 2 R 5 , SO 3 R 5 , SOR 5 , SONHR 5 , SO 2 NHR 5 , CN, CO 2 R 5 , COR 5 , PO 3 R 5 , PO(OR 5 ) 2 , and PO(OR 5 ), in which the aryl, heteroaryl, or heterocyclyl is optionally substituted with one or more R 30 ;
wherein R 2 is selected from the group consisting of R 1 , H, halogen, haloalkyl, C 1 -C 6 alkyl, C 2 -C 6 alkene, C 3 -C 7 cycloalkyl, OR 9 , SR 9 , N + (R 4 ) 3 , OCOR 6 , OCO 2 R 6 , NR 7 R 8 , NHSO 2 R 6 , NHCOR 6 , aryl, heteroaryl, and heterocyclyl;
wherein R 3 is selected from the group consisting of C 1 -C 6 alkyl, aryl-C 1 -C 6 alkyl, heteroaryl, and heterocyclyl;
wherein each R 4 is independently selected from the group consisting of OH and OC 1 -C 6 alkyl;
wherein each R 5 is independently selected from the group consisting of H, C 1 -C 6 alkyl, C 2 -C 6 alkene, C 3 -C 7 cycloalkyl, haloalkyl, aryl, heteroaryl, heterocyclyl, NHCH 2 C(O)OH, and (D) or (L) natural or non-natural amino acid optionally protected with an amino acid protecting group;
wherein each R 6 is independently selected from the group consisting of any (D) or (L) amino acid residue, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, aryl, heteroaryl, and heterocyclyl, in which the alkyl or cycloalkyl is optionally substituted with one or more R 10 substituents, and in which the aryl, heteroaryl, or heterocyclyl is optionally substituted with one or more R 20 substituents;
wherein R 7 and R 8 are independently selected from the group consisting of H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, haloalkyl, aryl, heteroaryl, and heterocyclyl, in which the alkyl or cycloalkyl is optionally substituted with one or more R 10 substituents, and in which the aryl, heteroaryl, or heterocyclyl is optionally substituted with one or more R 20 substituents;
wherein R 9 is selected from the group consisting of H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, aryl, heteroaryl, and heterocyclyl, in which the alkyl or cycloalkyl is optionally substituted with one or more R 10 substituents, and in which the aryl, heteroaryl, or heterocyclyl is optionally substituted with one or more R 20 substituents;
wherein each R 10 is independently selected from the group consisting of halogen, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, haloalkyl, aryl, heteroaryl, heterocyclyl, OR 9 , S(O) m R 9 , NR 7 R 8 , COR 9 , C(O)OR 9 , OC(O)R 9 , SC(O)R 9 , CONR 7 R 8 , and S(O) 2 NR 7 R 8 , wherein m is an integer of 0, 1, or 2;
wherein each R 20 is independently selected from the group consisting of halogen, NO 2 , CN, C 1 -C 6 alkyl, haloalkyl, C 3 -C 7 cycloalkyl, OR 7 , NR 7 R 8 , SR 7 , aryl, heteroaryl, heterocyclyl, SO 2 R 5 , SO 3 R 5 , SOR 5 , SONHR 5 , SO 2 NHR 5 , PO 3 R 5 , PO(OR 5 ) 2 , PO(OR 5 ), COR 5 , COR 7 , CO 2 R 7 , S(O) m R 7 , CONR 7 R 8 , S(O) 2 NR 7 R 8 , in which the alkyl or cycloalkyl is optionally substituted with one or more R 6 substituents, and in which the aryl, heteroaryl, or heterocyclyl is optionally substituted with one or more R 30 , wherein m is an integer of 0, 1, or 2; and
wherein each R 30 is independently selected from the group consisting of NO 2 , C 2 -C 6 alkene-R 20 , SO 2 R 5 , SOR 5 , SONHR 5 , SO 2 NHR 5 , CN, CO 2 R 5 , COR 5 , PO 3 R 5 , PO(OR 5 ) 2 , and PO(OR 5 );
or a pharmaceutically acceptable salt or ester thereof, or the compound is labeled with a detectable label or an affinity tag thereof, or combinations thereof wherein the compound is not one of the following compounds:
2. The compound of claim 1 , wherein R 1 is selected from the group consisting of SO 2 R 5 , SO 3 R 5 , and SOR 5 , and wherein R 5 is selected from the group consisting of C 1 -C 6 alkyl, aryl, and heterocyclyl.
3. The compound of claim 1 , wherein R 2 is selected from the group consisting of H, halogen, haloalkyl, C 1 -C 6 alkyl, and C 3 -C 7 cycloalkyl.
4. A compound according to Formula I:
wherein a is 0 or 1;
wherein b is 0 or 1 provided that when b is 0, a is 0;
wherein A is selected from the group consisting of H, C 1 -C 6 alkyl, aryl, heteroaryl, heterocyclyl, R 3 —OC(O)—, R 3 —CH 2 OC(O)—, and R 3 —S(O) 2 —;
wherein P2, P3, P4, and, when present, P5 and PX are each independently any (D) or (L) natural or non-natural amino acid residue;
wherein the line “-” when located between P2, P3, P4, P5, or PX represents a peptide bond or a peptidomimetic bond selected from the group consisting of CH 2 —NH, CO—CH 2 , azapeptide, and retro-inverso bonds;
wherein the wavy line represents either cis or trans orientation of R 1 and R 2 ;
wherein R 1 is selected from the group consisting of aryl, heteroaryl, heterocyclyl, C 2 -C 6 alkene-R 20 , SO 2 R 5 , SO 3 R 5 , SOR 5 , SONHR 5 , SO 2 NHR 5 , CN, CO 2 R 5 , COR 5 , PO 3 R 5 , PO(OR 5 ) 2 , and PO(OR 5 ), in which the aryl, heteroaryl, or heterocyclyl is optionally substituted with one or more R 30 ;
wherein R 2 is selected from the group consisting of R 1 , H, halogen, haloalkyl, C 1 -C 6 alkyl, C 2 -C 6 alkene, C 3 -C 7 cycloalkyl, OR 9 , SR 9 , N + (R 4 ) 3 , OCOR 6 , OCO 2 R 6 , NR 7 R 8 , NHSO 2 R 6 , NHCOR 6 , aryl, heteroaryl, and heterocyclyl;
wherein R 3 is selected from the group consisting of C 1 -C 6 alkyl, aryl-C 1 -C 6 alkyl, heteroaryl, and heterocyclyl;
wherein each R 4 is independently selected from the group consisting of OH and OC 1 -C 6 alkyl;
wherein each R 5 is independently selected from the group consisting of H, C 1 -C 6 alkyl, C 2 -C 6 alkene, C 3 -C 7 cycloalkyl, haloalkyl, aryl, heteroaryl, heterocyclyl, NHCH 2 C(O)OH, and (D) or (L) natural or non-natural amino acid optionally protected with an amino acid protecting group;
wherein each R 6 is independently selected from the group consisting of any (D) or (L) amino acid residue, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, aryl, heteroaryl, and heterocyclyl, in which the alkyl or cycloalkyl is optionally substituted with one or more R 10 substituents, and in which the aryl, heteroaryl, or heterocyclyl is optionally substituted with one or more R 20 substituents;
wherein R 7 and R 8 are independently selected from the group consisting of C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, haloalkyl, aryl, heteroaryl, and heterocyclyl, in which the alkyl or cycloalkyl is optionally substituted with one or more R 10 substituents, and in which the aryl, heteroaryl, or heterocyclyl is optionally substituted with one or more R 20 substituents;
wherein R 9 is selected from the group consisting of H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, aryl, heteroaryl, and heterocyclyl, in which the alkyl or cycloalkyl is optionally substituted with one or more R 10 substituents, and in which the aryl, heteroaryl, or heterocyclyl is optionally substituted with one or more R 20 substituents;
wherein each R 10 is independently selected from the group consisting of halogen, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, haloalkyl, aryl, heteroaryl, heterocyclyl, OR 9 , S(O) m R 9 , NR 7 R 8 , —COR 9 , C(O)OR 9 , OC(O)R 9 , SC(O)R 9 , CONR 7 R 8 , and S(O) 2 NR 7 R 8 , wherein m is an integer of 0, 1, or 2;
wherein each R 20 is independently selected from the group consisting of halogen, NO 2 , CN, C 1 -C 6 alkyl, haloalkyl, C 3 -C 7 cycloalkyl, OR 7 , NR 7 R 8 , SR 7 , aryl, heteroaryl, heterocyclyl, SO 2 R 5 , SO 3 R 5 , SOR 5 , SONHR 5 , SO 2 NHR 5 , PO 3 R 5 , PO(OR 5 ) 2 , PO(OR 5 ), COR 5 , COR 7 , CO 2 R 7 , S(O) m R 7 , CONR 7 R 8 , S(O) 2 NR 7 R 8 , in which the alkyl or cycloalkyl is optionally substituted with one or more R 6 substituents, and in which the aryl, heteroaryl, or heterocyclyl is optionally substituted with one or more R 30 , wherein m is an integer of 0, 1, or 2; and
wherein each R 30 is independently selected from the group consisting of NO 2 , C 2 -C 6 alkene-R 20 , SO 2 R 5 , SOR 5 , SONHR 5 , SO 2 NHR 5 , CN, CO 2 R 5 , COR 5 , PO 3 R 5 , PO(OR 5 ) 2 , and PO(OR 5 );
or a pharmaceutically acceptable salt or ester thereof, or the compound is labeled with a detectable label or an affinity tag thereof, or any combinations thereof; and
wherein the compound is not one of the following compounds